American Investment
Investing in America’s Future
America’s biopharmaceutical companies are expanding their manufacturing footprint and pioneering innovative research across the United States.
$500 billion in new biopharmaceutical investment will give a $1.2 trillion boost to America’s economy
Explore how PhRMA member companies are investing in new U.S.-based manufacturing and infrastructure, creating jobs and opportunities for Americans, their families and local communities.
Member Investment News
Strengthening the U.S. Economy
Source: TEConomy Partners, LLC. The Economic Impact of the U.S. Biopharmaceutical Industry: 2022 National and State Estimates. February 2024.
$1.6 trillion in economic output
Contributes substantially to the American economy, totaling more than $1.65 trillion in economic output (in 2022), which represents 3.6% of all U.S. output.
1,500+ facilities in 48 states
Operates 1,574 facilities across the country that are manufacturing innovative treatments (as of 2022).
5 million high-skilled jobs
Directly employs more than one million workers and supports an additional 3.8 million U.S. jobs indirectly.
111 million students in STEM programs
Supports 37 STEM education programs across the country, providing $180 million in financial support and reaching nearly 111 million students and 183,000 teachers.
Every day, our industry is working to bring treatments and cures to Americans.
More than 1 million employees of U.S. biopharmaceutical companies work every day to research and develop transformative treatments.
Our industry relies on a talented STEM workforce to advance innovation, which is why we’re committed to investing in the next generation of innovators through education programs at universities across the country.
We’re also working hard to develop new life-saving treatments through clinical trials across the country, with over 5,000 active clinical trial sites reaching more than 900,000 Americans.
Our industry supports America’s biopharmaceutical leadership.
Our industry’s investments and impact are driven by pro-innovation policies. Explore the biopharmaceutical clusters made possible by smart policy.
Protecting American Investment and Leadership in Biopharmaceutical Innovation
Robust, pro-innovation policies are critical to maintaining our country’s leadership and supporting patient access to transformative medicines.
Our Work in Action
To maintain America’s global leadership, we need to support the next generation of innovation in medicine.
